Hypercholesterolemia PCSK9 Survey

This survey is directed to persons with high levels of LDL (“bad”) cholesterol or their caregivers   A new class of drugs called PCSK9 inhibitors that include Repatha (evolocumab), Praluent (alirocumab), and bococizumab are used to treat high LDL  The first PCSK9 inhibitor, Repatha, will be reviewed by Canada’s Common Drug Review (CDR), to determine whether the drug should be funded by the provincial drug plans for treatment of (uncontrolled) high cholesterol. Patient groups have the opportunity to make a written submission to CDR as part of the review process.

This survey is being conducted by the FH Canada Patient Network (FH-CPN) and seeks feedback  from patients with the following characteristics: patients with high cholesterol on statins with or without other lipid-lowering therapies; patients who cannot tolerate statins; patients with heterozygous familial hypercholesterolemia (HeFH); and patients with homozygous familial hypercholesterolemia (HoFH), a rare and serious genetic disorder as well as caregivers.

We are seeking feedback on your experience of living with “high cholesterol”, how it affects you, your work, and your family life. We also want to know about any treatments you have received, now or in the past. We especially want feedback from patients who have used a PCSK9 inhibitor, Repatha (evolocumab), Praluent (alirocumab) or bococizumab.

Your answers are confidential and no personally identifiable  information will be shared with your healthcare provider, your insurance plan, workplace, or any other entity without your explicit permission.  Your responses will be summarized as part of the submission by FH-CPN to the Common Drug Review. No individually identifiable information will be submitted.

IMPORTANT DEADLINE: Please complete AS SOON AS POSSIBLE or no later than 22 July 2015. Our deadline for submission of analyzed responses is 24 July 2015.

To complete the survey use this link: https://www.surveymonkey.com/r/HypercholPCSK9